Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Eur Rev Med Pharmacol Sci ; 22(19): 6567-6572, 2018 10.
Article in English | MEDLINE | ID: mdl-30338829

ABSTRACT

OBJECTIVE: Myo-inositol supplementation prevents gestational diabetes (GDM) in women at risk and reduces insulin resistance in women with GDM. No data are available about its effect on glucose variability. The aim of this study was to evaluate the effects of a supplementation of myo-inositol on glucose variability in women with GDM. PATIENTS AND METHODS: Myo-inositol effect on glucose variability was studied in a pilot case-control study involving 12 consecutive pregnant women (median age 34 years, 25.0% insulin-treated) with GDM. Six women received myo-inositol 2 g plus 200 mg folic acid twice a day, the others received only folic acid. Information on side effects was collected. A continuous glucose monitoring system was wore before and at the beginning of the supplementation. Mean amplitude of glucose excursion (MAGE), standard deviation (SD) and variability coefficient were the indexes of glucose variability. RESULTS: Myo-inositol lowered glucose levels in the first days after the treatment was started. However, pre-post supplementation overall mean glucose difference was similar between groups (-4.8 vs. 5.0 mg/dL for controls and treated, respectively; p = 0.79). Pre-post differences in SD (13.7 vs. 6.0; p < 0.001), MAGE (3.5 vs.-1.5; p < 0.001) and variability coefficient (0.14 vs. 0.02; p < 0.001) were improved in myo-inositol group. No side effects were recorded. CONCLUSIONS: Myo-inositol is effective in reducing glucose variability in women with GDM. It could be a useful strategy for treating GDM.


Subject(s)
Blood Glucose/drug effects , Diabetes, Gestational/drug therapy , Dietary Supplements , Hypoglycemic Agents/therapeutic use , Inositol/therapeutic use , Adult , Biomarkers/blood , Blood Glucose/metabolism , Case-Control Studies , Diabetes, Gestational/blood , Diabetes, Gestational/diagnosis , Dietary Supplements/adverse effects , Down-Regulation , Female , Humans , Hypoglycemic Agents/adverse effects , Inositol/adverse effects , Pilot Projects , Pregnancy , Treatment Outcome
2.
J Matern Fetal Neonatal Med ; 27(14): 1445-8, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24175881

ABSTRACT

There is a debate about whether universal or risk factors-based screening is most appropriate for gestational diabetes diagnosis. The aim of our retrospective study was to compare in our population the universal screening test recommended by the International Association of Diabetes in Pregnancy Study Group (IADPSG) panel and the American Diabetes Association (ADA) versus the selective screening proposed by the United Kingdom National Institute for Health and Clinical Excellence guidelines (NICE) but modified by the Italian National Institute of Health. From May 2010 to October 2011 all consecutive pregnant women were screened for gestational diabetes according to the IADPSG's panel criteria, while all the risk factors for each patient were registered. Of the 1015 pregnant women included in the study, 113 (11%) were diagnosed with gestational diabetes and 26 (23%) of them would not have been identified by the selective screening proposed by the Italian National Institute of Health. However, all the risk factors considered by the selective screening revealed a good predictive role except for maternal age ≥ 35 years (OR: 0.98). In the group without the risk factors considered, it was reported the predictive role for gestational diabetes of prepregnancy BMI and nulliparity. The selective risk factors-based screening proposed by the Italian National Institute of Health has detected 77% of gestational diabetes cases in our population, sparing the oral glucose tolerance test for more than 40% of pregnant women at the same time. More information on the clinical impact of this choice could be obtained by a strict analysis of treatment, perinatal outcome and follow-up of an adequate sample size of "missed" gestational diabetes.


Subject(s)
Diabetes, Gestational/epidemiology , Mass Screening , Prenatal Diagnosis , Adult , Female , Glucose Tolerance Test , Humans , Italy/epidemiology , Mass Screening/methods , Mass Screening/standards , Maternal Age , Practice Guidelines as Topic , Pregnancy , Prenatal Diagnosis/methods , Prenatal Diagnosis/standards , Retrospective Studies , Risk Factors , Young Adult
3.
J Diabetes Res ; 2013: 486593, 2013.
Article in English | MEDLINE | ID: mdl-24171177

ABSTRACT

OBJECTIVES: of this study were to assess diastolic function in pregnant women with abnormal glucose tolerance (AGT), compared with normal glucose tolerance (NGT) women, and to evaluate the insulin resistance status and its association with Doppler-echocardiographic indexes. Echocardiograms of 108 consecutive Caucasian women with singleton pregnancies were performed. Insulin resistance status was estimated by the homeostasis model assessment of insulin resistance (HOMA-IR) and the quantitative insulin sensitivity check index (QUICKI). All the studied women showed normal diastolic patterns. Patients with AGT (50.9%), as compared with NGT women, had higher HOMA-IR (1.70 ± 1.30 versus 1.01 ± 0.81, P = 0.003), lower QUICKI (0.36 ± 0.005 versus 0.40 ± 0.06, P = 0.004), higher lateral mitral annulus late diastolic velocity (13.6 ± 4.9 versus 11.9 ± 4.9, P = 0.03), and higher A-wave velocity, the wave responsible for the active atrial contraction component (75.2 ± 14.2 versus 67.7 ± 16.2, P = 0.01). At multivariate regression analysis HOMA-IR was the only parameter associated with A-wave velocity. In conclusion, women with AGT had an increased subclinical diastolic active participation, which is associated with higher levels of insulin resistance. For the increased risk of deterioration of cardiac diastolic function, earlier and more seriously than normal pregnancy, AGT women may have a careful followup to detect the early signs of cardiac alteration and to prevent cardiovascular diseases.


Subject(s)
Cardiovascular Diseases/diagnostic imaging , Cardiovascular Diseases/prevention & control , Diastole , Glucose Intolerance/complications , Glucose Intolerance/diagnostic imaging , Pregnancy Complications, Cardiovascular/diagnostic imaging , Prenatal Diagnosis/methods , Adult , Asymptomatic Diseases , Case-Control Studies , Early Diagnosis , Echocardiography, Doppler , Female , Glucose Tolerance Test , Humans , Pregnancy , Pregnancy Complications, Cardiovascular/prevention & control , Young Adult
4.
J Endocrinol Invest ; 36(5): 347-251, 2013 May.
Article in English | MEDLINE | ID: mdl-23027769

ABSTRACT

BACKGROUND: Several studies have reported increased fracture risk in Type 1 diabetes mellitus (T1DM). Quantitative Ultrasound (QUS) provides information on the structure and elastic properties of bone, which are important determinants of fracture risk, along with bone mineral density. AIM: To study phalangeal sites by QUS, examine bone turnover markers and analyze association between these factors with metabolic control in a population of pre-menopausal women with T1DM. MATERIAL AND METHODS: Thirty-five T1DM pre-menopausal women (mean age 34.5 ± 6.8 yr) attending the Diabetic Outpatients Clinic in the Department of Internal Medicine, University of Messina, were consecutively enrolled and divided into two groups, taking into account the mean value of glycated hemoglobin in the last three years. Twenty healthy age-matched women served as controls. Phalangeal ultrasound measurements [Amplitude Dependent Speed of Sound (AD-SoS), Ultrasound Bone Profile Index (UBPI), TScore, Z-Score] were performed using a DBM Sonic Bone Profiler. Osteocalcin and deoxypyridinoline served as markers of bone formation and bone resorption, respectively. RESULTS: T1DM women with poor metabolic control showed lower phalangeal QUS values compared to healthy controls (p<0.01) and T1DM women with good metabolic control (p<0.05). No significant differences in QUS measurements were detected between T1DM women with good metabolic control and healthy controls. Lower bone formation and increased bone resorption, although not statistically significant, were observed in patients with poor metabolic control in comparison to patients with good metabolic control. CONCLUSIONS: Poor metabolic control may worsen the quality of bone in T1DM. Phalangeal QUS could be considered as a tool to screen T1DM women for osteoporosis in pre-menopausal age.


Subject(s)
Diabetes Mellitus, Type 1/therapy , Finger Phalanges/diagnostic imaging , Hyperglycemia/prevention & control , Hypoglycemia/prevention & control , Osteoporosis/diagnostic imaging , Adult , Biomarkers , Cross-Sectional Studies , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 1/complications , Early Diagnosis , Female , Hospitals, University , Humans , Italy , Osteoporosis/complications , Outpatient Clinics, Hospital , Ultrasonography, Doppler, Color , Young Adult
5.
Diabet Med ; 28(8): 972-5, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21414183

ABSTRACT

AIM: To test the hypothesis that myoinositol supplementation will improve insulin sensitivity as measured by markers of insulin resistance such as homeostasis model assessment of insulin resistance and adiponectin in women with gestational diabetes. METHODS: The trial was carried out in diet-treated patients with gestational diabetes diagnosed in our department between April 2008 and September 2009. Subjects were randomly assigned to receive either myoinositol supplementation (4 g daily) plus folic acid (400 µg daily)-the study group-or folic acid only (400 µg daily)-the control group. Both groups received the same diet prescription. Homeostasis model assessment of insulin resistance and adiponectin were assayed while fasting at the time of the diagnostic oral glucose tolerance test and after 8 weeks of treatment. RESULTS: There were 69 evaluable patients, 24 in the study group and 45 in the control group. Fasting glucose and insulin, and consequently homeostasis model assessment of insulin resistance, decreased in both groups (50% in the study group vs. 29% in the control group), but the decline in the study group was significantly greater than that in the control group (P = 0.0001). Adiponectin increased in the myoinositol group while it decreased in the control group (P = 0.009). CONCLUSION: Myoinositol improves insulin resistance in patients with gestational diabetes.


Subject(s)
Adiponectin/metabolism , Blood Glucose/drug effects , Diabetes, Gestational/drug therapy , Dietary Supplements , Inositol/therapeutic use , Insulin/metabolism , Adult , Blood Glucose/metabolism , Diabetes, Gestational/metabolism , Female , Glucose Tolerance Test , Humans , Hypoglycemic Agents , Inositol/metabolism , Insulin Resistance , Pregnancy , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...